



Docket No.: 02755/0205241-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Benjamin Oshlack and Mark Chasin

Application No.: 10/731,678

Group Art Unit: 1615

Filing Date: December 8, 2003

Examiner: Marc C. FITZGERALD

For: ORALLY ADMINSTRABLE OPIOID
FORMULATIONS HAVING EXTENDED
DURATION OF EFFECT

**RESPONSE TO OFFICE ACTION AND
AMENDMENT UNDER 37 C.F.R. § 1.111**

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action mailed on January 20, 2006 in connection with this application and pursuant to Rule 111 of the Rules of Practice, please enter the following amendments and consider the accompanying remarks.

An Amendment Transmittal Letter accompanies this Response, setting forth the estimated fee for this amendment. Applicants are also submitting herewith a Petition for Extension of Time and Fee Transmittal Form, along with a check in the amount of \$2,170.00 as payment of the estimate amendment and extension fees. It is believed that no other fees are required for these submissions. However, should the United States Patent and Trademark Office determine that any additional fee is required or that any refund is due, then the Commissioner is

07/25/2006 RMEBRAHT 00000127 10731678

01 FC:1201
02 FC:1202

600.00 OP
550.00 OP

hereby requested and authorized to charge the required fee(s) and/or credit the refund(s) due to Deposit Account No. 04-0100 of the undersigned attorneys/agents.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this document.

Remarks and Arguments begin on page 11 of this document.

* * * * *